Athersys

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. It engages in the discovery and development of therapies designed to extend and enhance the quality of human life. The firm offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analysis of Phase 3 MASTERS-2 clinical trial studying MultiStem for treatment of ischemic stroke indicating.

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

Lineage Cell Therapeutics Inc

Unity Biotechnology Inc

Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.

Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. (“Healios”) under the acute respiratory distr.

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company's ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients.

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

CLEVELAND & LEXINGTON, Ky.--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health (Ardent). Ardent is a privately held veterinary biotechnology company developing regenerative medicine and cancer therapies.

Athersys Licenses its Animal Health Assets to Ardent Animal Health

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company's recent 2023 Annual Meeting of Stockholders. Current Director Jane Wasman, JD, has been appointed Board Chair, effective September 28, 2023. Ms. Wasman has served as a Director of the Company since November 2020, currently serving as Chair of Athersys' Audit Committee and.

Athersys Director Jane Wasman Appointed Board Chair

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation's Medical Research Council to explore the potential use of Athersys' MultiStem cellular therapy during machine perfusion prior to kidney tra.

Grant Awarded to Newcastle University to Research Athersys' MultiStem® in Machine Perfusion Prior to Kidney Transplantation

Cano Health

eFFECTOR Therapeutics Inc

Genius Group Ltd

Canoo

Pieris Pharma

T2 Biosystems

Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.

7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?

Athersys (NASDAQ: ATHX ) stock is falling on Friday after the biotechnology company announced a public stock offering. That public offering has Athersys selling 10,937,500 shares of ATHX stock for a price of 32 cents each.

Why Is Athersys (ATHX) Stock Down 36% Today?

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), today announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.32 per share. The Company further agreed to issue to the investors Series A Warrants to purchase up to an aggregate of 10,937,500 shares of common stock and Series B Warrants to purchase up to an aggregate of 10,937,500 shares of common stock. The Series.

Athersys, Inc. Announces Pricing of $3.5 Million Public Offering

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update. Second Quarter 2023 and Recent Corporate and Operational Highlights: Nominated healthcare executive and strategy consultant Neema Mayhugh, Ph.D. to the Company's Board of Directors Surpassed two-thirds patient enrollm.

Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings. Dr. Mayhugh currently serves as the Founder and Managing Partner of Wave Strategy, a consultancy focused on the rapid commer.

Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscienc.

Athersys to Host Business Update Conference Call on August 9th

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients following resuscitation from hemorrhagic trauma. This study is being conducted at The University of Texas Health Science Center at Houston (UTHealth Houston) and Memorial Hermann-Tex.

Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys' MultiStem® Following Hemorrhagic Trauma

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier (“the supplier”). The Company previously entered into agreements with the supplier to assist in the scale-up and manufacturing of clinical and commercial grade MultiStem® using Athersys' bioreactor production processes. Under the new agreement, Athersys will p.

Athersys Restructures Debt with Supplier

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended March 31, 2023 and provided a business update. First Quarter 2023 and Recent Corporate and Operational Highlights Continued reducing expenses to conserve cash and heightened focus on MASTERS-2 trial, thereby making Athersys more attractive to potentia.

Athersys Reports First Quarter 2023 Financial Results and Business Highlights

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today its participation in three upcoming conferences during the month of May. Chris Temple, Vice President of Operations, will be participating in the Pharma Manufacturing World Summit and Allogeneic Cell Therapies Summit, both in Boston, Massachusetts. Dr. Sarah Busch, Vice President of Regenerative Medicine and.

Athersys to Participate in Three Upcoming Conferences

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care's (CTTACC) conference, “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care,” from May 8-11, 2023 in Scottsdale, Arizona. Presented by the University of California San Francisco and Colorado State University, this.

Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL.

Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the “Shares”) of the Company's common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase 3,685,000 Shares at a purchase price per Share (and accompanying warrant) of $1.00 in a concurrent private placement (together with the registered direct offering, the “offering”).

Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the “Shares”) of the Company's common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 3,685,000 Shares at a purchase price per Share (and accompanying warrant) of $1.00 in a concurrent private placement (together with the registered direct offering, the “offering”

Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time.

Athersys to Host Business Update Conference Call on April 20th

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) today announced financial results for the three and 12 months ended December 31, 2022, and provided a business update.

Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced planned amendments to its MASTERS-2 clinical trial protocol following a Type B meeting with the U.S. Food & Drug Administration (FDA).

Athersys Announces Successful Type B Meeting with the FDA

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that the United States Patent and Trademark Office has granted the Company a new patent for its novel cryogenic storage system, the Secure Integrated Freezer Unit (SIFU®). This U.S. Patent No.

News for Athersys Stock (ATHX)